Denmark could become the First country to eliminate Cervical Cancer by 2040

Varshith SV
Varshith SV
· 2 min read

Denmark may be on track to eliminate cervical cancer within the next 15 years, according to a new report from the NGO, the Danish Cancer Society (Kræftens Bekæmpelse).

The report suggests that, based on current trends in vaccination and screening, the disease could reach elimination levels before 2040. Cervical cancer is considered eradicated by the World Health Organization (WHO) when fewer than four women per 100,000 are diagnosed annually. Denmark’s current rate is already below 10 per 100,000 women.

The key reason behind this decline is Denmark’s long-standing national HPV vaccination and screening programmes. The country introduced free HPV vaccines for girls in 2008 and for boys in 2019. About 89 per cent of 12-year-old girls and boys receive the first of two vaccine doses—just one per cent shy of the WHO’s recommended 90 per cent. The vaccination helps protect against the human papillomavirus (HPV), the leading cause of cervical cancer.

Denmark also offers free cervical screening for women, with about 60 per cent of those eligible participating. While this is slightly below the 70 per cent target, it contributes significantly to early detection and prevention.

The Danish Cancer Society stated that if the trends continue, the number of new cervical cancer cases could fall below the threshold for eradication well before 2040. If this happens, it would mark the first time any country has eliminated cancer.

Neighbouring Sweden, however, might reach the milestone even sooner. According to the Regional Cancer Centres in Sweden, it has set a goal to eliminate cervical cancer by 2027.

Read Next

Agenus announces closing of $141 M strategic collaboration with Zydus Lifesciences
Global News
January 20, 2026

Agenus announces closing of $141 M strategic collaboration with Zydus Lifesciences

To advance BOT+BAL and strengthen US manufacturing readiness Agenus, a leader in immuno-oncology innovation, announced the closing of its previously disclosed strategic collaboration with Zydus Lifesciences Ltd. The agreement is designed to accelerate global development and potential commercialisation of Agenus’ botensilimab and balstilimab (BOT+BAL) immunotherapy combination programme. The collaboration provides Agenus with strategic capital and […]
Article by: IMT News Desk
Venus Remedies secures marketing authorisation for Ceftazidime + Avibactam in Indonesia
Global News
January 16, 2026

Venus Remedies secures marketing authorisation for Ceftazidime + Avibactam in Indonesia

Approval marks Venus Remedies’ first anti-infective marketing authorisation in Indonesia and enables the country’s first generic entry for this critical antibiotic combination Venus Remedies has secured the marketing authorisation from the Indonesian regulatory authority for its combination antibiotic, Ceftazidime + Avibactam. This approval represents Venus Remedies’ first marketing authorization in the anti-infective segment in Indonesia […]
Article by: IMT News Desk
Wegovy pill approved in the US for weight management
Global News
December 26, 2025

Wegovy pill approved in the US for weight management

Novo Nordisk expects to launch the Wegovy pill in the US in early January 2026 Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse […]
Article by: IMT News Desk
Samsung Biologics America in agreement to acquire 100 per cent of Human Genome Sciences from GSK
Global News
December 24, 2025

Samsung Biologics America in agreement to acquire 100 per cent of Human Genome Sciences from GSK

Under the terms of the agreement, with closing anticipated toward the end of Q1 of 2026, Samsung Biologics will acquire the Rockville assets for $280 million Samsung Biologics, a leading contract development and manufacturing organization (CDMO), announced that its wholly owned US subsidiary, Samsung Biologics America, has entered into a definitive agreement to acquire 100 […]
Article by: IMT News Desk